Current and historical daily PE Ratio for HighTide Therapeutics Inc (
HKSE:02511
) from 2023 to Jun 07 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. HighTide Therapeutics stock (HKSE:02511) PE ratio as of Jun 07 2024 is 0.
More Details
HighTide Therapeutics Inc (HKSE:02511) PE Ratio (TTM) Chart
HighTide Therapeutics Inc (HKSE:02511) PE Ratio (TTM) Historical Data
View and export this data going back to 2023. Start your Free Trial
Total 111
- 1
- 2
| HighTide Therapeutics PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-06-07 | At Loss | 2024-04-02 | At Loss |
| 2024-06-06 | At Loss | 2024-03-28 | At Loss |
| 2024-06-05 | At Loss | 2024-03-27 | At Loss |
| 2024-06-04 | At Loss | 2024-03-26 | At Loss |
| 2024-06-03 | At Loss | 2024-03-25 | At Loss |
| 2024-05-31 | At Loss | 2024-03-22 | At Loss |
| 2024-05-30 | At Loss | 2024-03-21 | At Loss |
| 2024-05-29 | At Loss | 2024-03-20 | At Loss |
| 2024-05-28 | At Loss | 2024-03-19 | At Loss |
| 2024-05-27 | At Loss | 2024-03-18 | At Loss |
| 2024-05-24 | At Loss | 2024-03-15 | At Loss |
| 2024-05-23 | At Loss | 2024-03-14 | At Loss |
| 2024-05-22 | At Loss | 2024-03-13 | At Loss |
| 2024-05-21 | At Loss | 2024-03-12 | At Loss |
| 2024-05-20 | At Loss | 2024-03-11 | At Loss |
| 2024-05-17 | At Loss | 2024-03-08 | At Loss |
| 2024-05-16 | At Loss | 2024-03-07 | At Loss |
| 2024-05-14 | At Loss | 2024-03-06 | At Loss |
| 2024-05-13 | At Loss | 2024-03-05 | At Loss |
| 2024-05-10 | At Loss | 2024-03-04 | At Loss |
| 2024-05-09 | At Loss | 2024-03-01 | At Loss |
| 2024-05-08 | At Loss | 2024-02-29 | At Loss |
| 2024-05-07 | At Loss | 2024-02-28 | At Loss |
| 2024-05-06 | At Loss | 2024-02-27 | At Loss |
| 2024-05-03 | At Loss | 2024-02-26 | At Loss |
| 2024-05-02 | At Loss | 2024-02-23 | At Loss |
| 2024-04-30 | At Loss | 2024-02-22 | At Loss |
| 2024-04-29 | At Loss | 2024-02-21 | At Loss |
| 2024-04-26 | At Loss | 2024-02-20 | At Loss |
| 2024-04-25 | At Loss | 2024-02-19 | At Loss |
| 2024-04-24 | At Loss | 2024-02-16 | At Loss |
| 2024-04-23 | At Loss | 2024-02-15 | At Loss |
| 2024-04-22 | At Loss | 2024-02-14 | At Loss |
| 2024-04-19 | At Loss | 2024-02-09 | At Loss |
| 2024-04-18 | At Loss | 2024-02-08 | At Loss |
| 2024-04-17 | At Loss | 2024-02-07 | At Loss |
| 2024-04-16 | At Loss | 2024-02-06 | At Loss |
| 2024-04-15 | At Loss | 2024-02-05 | At Loss |
| 2024-04-12 | At Loss | 2024-02-02 | At Loss |
| 2024-04-11 | At Loss | 2024-02-01 | At Loss |
| 2024-04-10 | At Loss | 2024-01-31 | At Loss |
| 2024-04-09 | At Loss | 2024-01-30 | At Loss |
| 2024-04-08 | At Loss | 2024-01-29 | At Loss |
| 2024-04-05 | At Loss | 2024-01-26 | At Loss |
| 2024-04-03 | At Loss | 2024-01-25 | At Loss |
HighTide Therapeutics Inc (HKSE:02511) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
HighTide Therapeutics Inc
ISIN : KYG4568L1023
Description
HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The company has developed a product pipeline of five product candidates in-house, covering nine indications in metabolic and digestive diseases among which, five are at clinical-stage. The Core Product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers